デフォルト表紙
市場調査レポート
商品コード
1347531

潰瘍性大腸炎市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日: | 発行: IMARC | ページ情報: 英文 146 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
潰瘍性大腸炎市場:世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年09月04日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場概要:

潰瘍性大腸炎の世界市場規模は2022年に74億米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて5.4%の成長率(CAGR)を示し、2028年までに102億米ドルに達すると予測しています。

潰瘍性大腸炎(UC)は、消化管の炎症、炎症、潰瘍(ただれ)を引き起こす慢性炎症性腸疾患(IBD)です。通常、大腸(または結腸)と直腸の内壁が侵されます。一般的に症状は時間とともに進行し、UCと診断された患者さんでは、症状が軽かったり、全くなかったりする期間もあります。しかし、時には衰弱や生命を脅かす合併症を引き起こすこともあります。UCを完治させる治療法はまだ存在しないが、治療によって患者の症状を管理・軽減し、再燃を防ぎ、長期的な寛解をもたらすことができます。その結果、潰瘍性大腸炎治療は、患者の生活の質を高め、肉体的・精神的な健康を確保するのに役立つため、世界中で急速に普及しています。

潰瘍性大腸炎の市場動向:

潰瘍性大腸炎が広く蔓延し、利用可能な治療オプションに関する認識が高まっていることが、市場成長を促進する主な要因となっています。これに加えて、強力なパイプライン製品の存在と多数の薬剤の継続的な進歩が製品需要を増大させています。さらに、各国政府はこの疾患に関する認識を広め、適切なヘルスケア施設へのアクセスや利用可能性を高めるために、いくつかのイニシアチブをとっています。これは、新規治療法の開発のための研究開発(R&D)活動への投資の増加と相まって、市場の成長を促進しています。さらに、大手企業は製品ポートフォリオを拡大し、市場での競争力を高めるため、革新的でより効果的な医薬品の上市に注力しています。バイオシミラー医薬品の容易な入手可能性、ヘルスケアインフラの改善、有利な償還政策、ヘルスケアに対する消費者支出の増加など、その他の要因もまた、市場の前向きな見通しを生み出しています。

本レポートで扱う主な質問

  • 潰瘍性大腸炎の世界市場はこれまでどのように推移し、今後どのように推移するのか?
  • 潰瘍性大腸炎の世界市場におけるCOVID-19の影響は?
  • 主要な地域市場は?
  • タイプ別の市場内訳は?
  • 疾患タイプ別の市場内訳は?
  • 分子タイプ別の市場内訳は?
  • 薬剤タイプ別の市場内訳は?
  • 投与経路別の市場内訳は?
  • 販売チャネル別の市場内訳は?
  • 業界のバリューチェーンにおける様々な段階とは?
  • 業界の主な促進要因と課題は何か?
  • 潰瘍性大腸炎の世界市場構造と主要プレイヤーは?
  • 業界における競合の程度は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 潰瘍性大腸炎の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:タイプ別

  • 軽症UC
    • 市場動向
    • 市場予測
  • 中等症UC
    • 市場動向
    • 市場予測
  • 重症UC
    • 市場動向
    • 市場予測

第7章 市場内訳:疾患タイプ別

  • 潰瘍性直腸炎
    • 市場動向
    • 市場予測
  • 肛門直腸炎
    • 市場動向
    • 市場予測
  • 左側大腸炎
    • 市場動向
    • 市場予測
  • 全大腸炎
    • 市場動向
    • 市場予測
  • 劇症型大腸炎
    • 市場動向
    • 市場予測

第8章 市場内訳:分子タイプ別

  • 低分子
    • 市場動向
    • 市場予測
  • バイオロジクス
    • 市場動向
    • 市場予測

第9章 市場内訳:薬剤タイプ別

  • 抗炎症薬
    • 市場動向
    • 市場予測
  • 抗TNF生物学的製剤
    • 市場動向
    • 市場予測
  • 免疫抑制剤
    • 市場動向
    • 市場予測
  • カルシニューリン阻害剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳:投与経路別

  • 経口剤
    • 市場動向
    • 市場予測
  • 注射剤
    • 市場動向
    • 市場予測

第11章 市場内訳:流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • ドラッグストア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第12章 市場内訳:地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第13章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第16章 価格分析

第17章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
  • Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2022
  • Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2022
  • Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2022
  • Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2022
  • Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2022
  • Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2022
  • Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2022
  • Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
  • Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
  • Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million US$), 2023-2028
  • Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 9: Global: Ulcerative Colitis Market: Competitive Structure
  • Table 10: Global: Ulcerative Colitis Market: Key Players
目次
Product Code: SR112023A5663

Market Overview:

The global ulcerative colitis market size reached US$ 7.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2023-2028.

Ulcerative colitis (UC) refers to a chronic inflammatory bowel disease (IBD) that causes irritation, inflammation, and ulcers (sores) in the digestive tract. It typically affects the inner lining of the large intestine (or colon) and rectum. The symptoms generally develop over time, and individuals diagnosed with UC may experience periods of mild or no symptoms. However, it can sometimes lead to debilitating or life-threatening complications. While there is no cure for UC yet, the treatment can help patients manage and reduce their symptoms, prevent flare-ups, and bring about long-term remission. As a result, UC treatment is rapidly gaining traction across the globe as it can help enhance the quality of life and ensure the physical and mental wellbeing of the patients.

Ulcerative Colitis Market Trends:

The widespread prevalence of UC disease and the rising awareness regarding the available treatment options represent the primary factors driving the market growth. Besides this, the presence of strong pipeline products and continuous advancements in numerous drugs are augmenting the product demand. Additionally, governments of various countries are taking several initiatives to spread awareness about the condition and enhance the accessibility and availability of proper healthcare facilities. This, in confluence with the increasing investments in the research and development (R&D) activities for the development of novel therapies, is propelling the market growth. Furthermore, the leading players are focusing on launching innovative and more effective drugs to expand their product portfolio and gain a competitive edge in the market. Other factors, including the easy availability of biosimilar drugs, improving healthcare infrastructure, favorable reimbursement policies, and increasing consumer spending on healthcare, are also creating a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ulcerative colitis market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease type, molecule type, drug type, route of administration and distribution channel.

Breakup by Type:

Mild UC

Moderate UC

Severe UC

Breakup by Disease Type:

Ulcerative Proctitis

Proctosigmoiditis

Left-sided Colitis

Pancolitis or Universal Colitis

Fulminant Colitis

Breakup by Molecule Type:

Small Molecules

Biologics

Breakup by Drug Type:

Anti-Inflammatory Drugs

Anti-TNF Biologics

Immunosuppressant

Calcineurin Inhibitors

Others

Breakup by Route of Administration:

Oral

Injectable

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Store

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ulcerative colitis market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the disease type?
  • What is the breakup of the market based on the molecule type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global ulcerative colitis market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Moderate UC
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Severe UC
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proctosigmoiditis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Left-sided Colitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Fulminant Colitis
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Immunosuppressant
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Injectable
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Store
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Abbott Laboratories
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 AbbVie Inc.
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
      • 17.3.2.4 SWOT Analysis
    • 17.3.3 AstraZeneca plc
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 Financials
      • 17.3.3.4 SWOT Analysis
    • 17.3.4 Bristol-Myers Squibb Company
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
      • 17.3.4.3 Financials
      • 17.3.4.4 SWOT Analysis
    • 17.3.5 Eli Lilly and Company
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 F. Hoffmann-La Roche Ltd.
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
    • 17.3.7 GlaxoSmithKline plc
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 Johnson & Johnson
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 Merck & Co. Inc.
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
      • 17.3.9.3 Financials
      • 17.3.9.4 SWOT Analysis
    • 17.3.10 Pfizer Inc.
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 Financials
      • 17.3.10.4 SWOT Analysis
    • 17.3.11 Takeda Pharmaceutical Company Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis
    • 17.3.12 Teva Pharmaceutical Industries Ltd.
      • 17.3.12.1 Company Overview
      • 17.3.12.2 Product Portfolio
      • 17.3.12.3 Financials
      • 17.3.12.4 SWOT Analysis